19 Recruiting Recurrent Multiple Myeloma Clinical Trials
Explore open interventional and observational research studies actively enrolling participants across the USA. Verify eligibility and contact site coordinators directly.
📍 Find Near Me by DistanceTop Recruiting Recurrent Multiple Myeloma Studies
Dasatinib and Quercetin With CAR-T Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma
📍 Mayo Clinic in Rochester — Rochester, Minnesota
View Study & Checklist ➔Allogeneic ORCA-Q Stem Cell Transplant for the Treatment of Relapsed and Refractory High Risk Multiple Myeloma
📍 University of California Davis Comprehensive Cancer Center — Sacramento, California
View Study & Checklist ➔Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial
📍 Mayo Clinic in Rochester — Rochester, Minnesota
View Study & Checklist ➔Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma
📍 Mayo Clinic Hospital in Arizona — Phoenix, Arizona
View Study & Checklist ➔Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma
📍 Mary Greeley Medical Center — Ames, Iowa
View Study & Checklist ➔Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted Therapies
📍 Ohio State University Comprehensive Cancer Center — Columbus, Ohio
View Study & Checklist ➔Alternate Doses and Dosing Schedules of Belantamab Mafodotin for Treatment of Triple-Class Refractory Multiple Myeloma
📍 Mayo Clinic in Florida — Jacksonville, Florida
View Study & Checklist ➔Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma
📍 Mayo Clinic in Rochester — Rochester, Minnesota
View Study & Checklist ➔CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma
📍 Yale University — New Haven, Connecticut
View Study & Checklist ➔Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma
📍 Fred Hutch/University of Washington Cancer Consortium — Seattle, Washington
View Study & Checklist ➔Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment
📍 ECOG-ACRIN Cancer Research Group — Philadelphia, Pennsylvania
View Study & Checklist ➔Response-Based Dose Reduction of Linvoseltamab in the Treatment of Relapsed, Refractory, or Triple-Class Relapsed/Refractory Multiple Myeloma
📍 Fred Hutch/University of Washington Cancer Consortium — Seattle, Washington
View Study & Checklist ➔SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
📍 Roswell Park Comprehensive Cancer Center — Buffalo, New York
View Study & Checklist ➔